WINDSOR JAMES BRIAN 4
4 · TFF Pharmaceuticals, Inc. · Filed Dec 9, 2020
Insider Transaction Report
Form 4
WINDSOR JAMES BRIAN
DirectorChief Science Officer
Transactions
- Exercise/Conversion
Stock Options (Right to Buy)
2020-12-07−25,000→ 134,429 totalExercise: $2.50From: 2019-09-26Exp: 2028-09-26→ Common Stock (25,000 underlying) - Exercise/Conversion
Common Stock
2020-12-07$2.50/sh+25,000$62,500→ 30,000 total - Sale
Common Stock
2020-12-07$15.80/sh−25,000$395,000→ 5,000 total
Footnotes (2)
- [F1]The transactions reported by this Form 4 reflect the Reporting Person's exercise of options to purchase common shares pursuant to Rule 16b-3 under the Securities Exchange Act of 1934 and the Reporting Person's concurrent sale of the common shares acquired upon the exercise of the options.
- [F2]18,003 shares of common stock vested on September 26, 2019 and the remainder of the shares vested at an approximate rate of 4,500 every three months thereafter.